Detection and long-term quantification of methane emissions from an active landfill

Landfills are a significant source of fugitive methane (CH4) emissions, which should be precisely and regularly monitored to reduce and mitigate net greenhouse gas emissions. In this study, we present long-term, in situ, near-surface, mobile atmospheric CH4 mole fraction measurements (complemented by meteorological measurements from a fixed station) from 21 campaigns that cover approximately 4 years from September 2016 to December 2020. These campaigns were utilized to regularly quantify the total CH4 emissions from an active landfill in France. We use a simple atmospheric inversion approach based on a Gaussian plume dispersion model to derive CH4 emissions. Together with the measurements near the soil surface, mainly dedicated to the identification of sources within the landfill, measurements of CH4 made on the landfill perimeter (near-field) helped us to identify the main emission areas and to provide some qualitative insights about the rank of their contributions to total emissions from the landfill. The two main area sources correspond, respectively, to a covered waste sector with infrastructure with sporadic leakages (such as wells, tanks, pipes, etc.) and to the last active sector receiving waste during most of the measurement campaigns. However, we hardly managed to extract a signal representative of the overall landfill emissions from the near-field measurements, which limited our ability to derive robust estimates of the emissions when assimilating them in the atmospheric inversions. The analysis shows that the inversions based on the measurements from a remote road further away from the landfill (far-field) yielded reliable estimates of the total emissions but provided less information on the spatial variability of emissions within the landfill. This demonstrates the complementarity between the near- and far-field measurements. According to these inversions, the total CH4 emissions have a large temporal variability and range from ∼ 0.4 to ∼ 7 t CH4 d−1, with an average value of ∼ 2.1 t CH4 d−1. We find a weak negative correlation between these estimates of the CH4 emissions and atmospheric pressure for the active landfill. However, this weak emission–pressure relationship is based on a relatively small sample of reliable emission estimates with large sampling gaps. More frequent robust estimations are required to better understand this relationship for an active landfill.</p

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation &lt;92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p&lt;0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p&lt;0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Does Holling's disc equation explain the functional response of a kleptoparasite?

1. Type II functional responses, which can be described by Holling's disc equation, have been found in many studies of predator/prey and host/parasite interactions. However, an increasing number of studies have shown that the assumptions on which the disc equation is based do not necessarily hold. We examine the functional response of kleptoparasitically feeding Arctic skuas (Stercorarius parasiticus L.) to the abundance of fish-carrying auks and, by examination of the assumptions of the disc equation, test whether it can explain the function. 2. The rate at which individual skuas make successful chases is a decelerating function of the abundance of auks. However, it would appear that this is not determined by factors that influence their probability of success, but by the rate at which they initiate chases. This too is a decelerating function of the abundance of auks, Arctic skuas have a Type II functional response. 3. Although Arctic skuas exhibited a direct numerical response there was no evidence that components of predation connected to the density of predators (direct prey stealing, or increased host avoidance) had any effect on the rate at which individual skuas made chases or were successful in their chases, We conclude that the observed functional response is free from any effects of interference. 4. We suggest that abnormally high levels of foraging effort expended by breeding skuas and their poor breeding success in the years of observation argue against the limit to the observed functional response being determined by skuas' energetic requirements 5. Several of the assumptions underlying the disc equation do not hold. The duration of chases (handling time) was not a constant; it decreased with increasing host abundance, Moreover, the chase duration predicted by the disc equation, if handling time limited the functional response, was far in excess of that observed. Furthermore, the observed rate of decline in the searching time per victim with increasing host abundance suggested that skuas' instantaneous rate of discovery was also not constant. Possible reasons for these observations are discussed. The basic disc equation may describe Arctic skuas' functional response, but it cannot explain i